发明申请
US20090203751A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
有权
新型1,2,4-噻二唑衍生物作为黑皮质素受体调节剂
- 专利标题： Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
- 专利标题（中）： 新型1,2,4-噻二唑衍生物作为黑皮质素受体调节剂
-
申请号： US12221900申请日： 2008-08-05
-
公开(公告)号： US20090203751A1公开(公告)日： 2009-08-13
- 发明人: Magdalena Eisinger Eisinger , Louis J. Fitzpatrick , Daniel H. Lee , Kevin Pan , Carlos Plata-Salaman , Allen B. Reitz , Virginia L. Smith-Swintosky , Boyu Zhao
- 申请人： Magdalena Eisinger Eisinger , Louis J. Fitzpatrick , Daniel H. Lee , Kevin Pan , Carlos Plata-Salaman , Allen B. Reitz , Virginia L. Smith-Swintosky , Boyu Zhao
- 主分类号： A61K31/433
- IPC分类号： A61K31/433 ; A61P3/00 ; A61P17/00 ; C07C335/04
摘要：
The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.
公开/授权文献
信息查询
